The severe deficiency of ADAMTS13 has also gained attention due to the development of a rare TMA, called immune-mediated thrombotic thrombocytopenic purpura [71,72], caused by the production of anti-ADAMTS13 antibodies, in a limited number of subjects after COVID-19 vaccination. Here, ADAMTS13 is linked to COVID-19.